Flu shots generally reduce the risk of illness from influenza viruses by 40 percent to 60 percent. Their effectiveness varies because influenza viruses are always changing, and scientists have to determine which strains they believe will be most prevalent in a certain flu season, CNBC reported.
But mRNA vaccines are more flexible, and scientists could quickly pivot and adjust an mRNA-based flu shot to match the more dominant strain, according to CNBC.
“I think the great success of the mRNA vaccines in addressing COVID-19 has clearly opened up a large number of possibilities,” Dr. Jansen told CNBC.
Pfizer and BioNTech’s COVID-19 vaccine was the first time mRNA technology was cleared for use in humans, although it has been in development for years. It’s said to be easier to produce than traditional vaccines, according to CNBC.
Moderna has said it will work on developing a flu shot using mRNA technology.
Read the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
